Skip to main content

Table 1 Baseline characteristics of patients

From: Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study

 

Patients treated with pirfenidone

Patients never treated with pirfenidone

Total (n = 142)

Autoantibody ( −) (n = 93)

Autoantibody ( +) (n = 49)

Total (n = 92)

Autoantibody ( −) (n = 57)

Autoantibody ( +) (n = 35)

Sex (male)

110 (77.5%)

71 (76.3%)

39 (79.6%)

64 (69.6%)

40 (70.2%)

724(68.6%)

Age (year)

69.5 ± 7.3

70.0 ± 6.8

68.5 ± 8.0

67.1 ± 10.3

67.1 ± 11.2

67.0 ± 8.7

BMI (kg/m2)

24.8 ± 2.9

25.2 ± 3.0

24.0 ± 2.7

23.3 ± 3.0

23.2 ± 3.2

23.5 ± 2.6

Smoking exposure (%)

 Never

43 (30.3%)

32 (34.4%)

11 (22.4%)

7 (7.6%)

4 (7.0%)

3 (8.6%)

 Former

80 (56.3%)

50 (53.8%)

30 (61.2%)

51 (55.4%)

34 (59.6%)

17 (48.6%)

 Current

19 (13.4%)

11 (11.8%)

8 (16.3%)

34 (37.0%)

19 (33.3%)

15 (42.9%)

Smoking (pack-years)

20.0 (0.0–40.0)

20.0 (0.0–36.0)

30.0 (6.0–45.0)

15.0 (0.0–32.5)

20.0 (0.0–35.0)

4.2 (0.0–30.0)

Comorbidities

 Hypertension

30 (21.1%)

23 (24.7%)

7 (14.3%)

44 (47.8%)

28 (49.1%)

16 (45.7%)

 Diabetes mellitus

38 (26.8%)

30 (32.3%)

8 (16.3%)

24 (26.1%)

19 (33.3%)

5 (14.3%)

 GERD

46 (32.4%)

30 (32.3%)

16 (32.7%)

27 (29.3%)

19 (33.3%)

8 (22.9%)

 Asthma

11 (7.7%)

9 (9.7%)

2 (4.1%)

5 (5.4%)

3 (5.3%)

2 (5.7%)

 Old pulmonary tuberculosis

28 (19.7%)

19 (20.4%)

9 (18.4%)

18 (19.6%)

13 (22.8%)

5 (14.3%)

 Cancer

29 (20.4%)

18 (19.4%)

11 (22.4%)

23 (25.0%)

17 (29.8%)

6 (17.1%)

 Coronary artery disease

25 (19.6%)

14 (15.1%)

11 (22.4%)

19 (20.7%)

11 (19.3%)

8 (22.9%)

 Cerebrovascular disease

4 (2.8%)

4 (4.3%)

0 (0.0%)

5 (5.4%)

5 (8.8%)

0 (0.0%)

Pulmonary function test (at IPF diagnosis)

 FVC (L)

2.6 ± 0.7

2.7 ± 0.7

2.6 ± 0.6

2.8 ± 0.9

2.8 ± 0.9

2.8 ± 0.8

 FVC % pred

77.0 ± 13.0

78.2 ± 13.9

74.7 ± 10.8

83.6 ± 20.0

81.8 ± 20.6

86.5 ± 18.8

 FEV1 (L)

2.1 ± 0.5

2.1 ± 0.5

2.1 ± 0.4

2.2 ± 0.7

2.2 ± 0.7

2.2 ± 0.6

 FEV1% pred

90.7 ± 15.0

91.5 ± 14.8

89.3 ± 15.4

96.2 ± 22.6

94.5 ± 23.5

99.1 ± 21.1

 DLCO (mL/mmHg/min)

10.8 (8.7–13.2)

11.1 (8.7–13.6)

9.8 (8.6–12.0)

13.0 ± 4.6

13.4 ± 4.6

12.2 ± 4.5

 DLCO % pred

63.0 (53.0–73.0)

65.0 (55.0–76.0)

60.0 (52.0–72.0)

70.5 ± 24.4

72.9 ± 25.9

66.7 ± 21.6

Obstructive pattern

8 (5.6%)

5 (5.4%)

3 (6.1%)

7 (7.6%)

5 (8.8%)

2 (5.7%)

Severity of IPF (GAP index)

 I

126 (88.7%)

81 (87.1%)

45 (91.8%)

48 (84.2%)

48 (84.2%)

32 (91.4%)

 II

16 (11.3%)

12 (12.9%)

4 (8.2%)

9 (15.8%)

9 (15.8%)

3 (8.6%)

Follow-up period (months)

24.4 (14.9–32.7)

24.4 (16.6–32.2)

24.2 (11.7–32.7)

31.1 (12.6–54.8)

28.7 (13.8–52.7)

40.3 (12.3–56.0)

Acute exacerbation

26 (18.3%)

20 (21.5%)

6 (12.2%)

13 (14.1%)

10 (17.5%)

3 (8.6%)

Pirfenidone dose (mg)

1184.5 (837.3–1467.3)

1185.6 (890.7–1398.0)

1183.5 (836.0–1550.2)

CT scan patterna

 UIP

124 (87.3%)

86 (92.5%)

38 (77.6%)

76 (82.6%)

48 (84.2%)

28 (80.0%)

 Possible UIP

18 (12.7%)

7 (7.5%)

11 (22.4%)

16 (17.4%)

9 (15.8%)

7 (20.0%)

UIP by surgical lung biopsy

44 (31.0%)

26 (28.0%)

18 (36.7%)

30 (32.6%)

18 (31.6%)

12 (34.3%)

  1. Values are expressed as mean ± standard deviation, number (%) or mean (interquartile range)
  2. BMI body mass index, DLCO diffusing capacity of the lungs for carbon monoxide, FEV1 forced expiratory volume in one second, FVC forced vital capacity, GAP gender, age, and physiology, GERD gastroesophageal reflux disease, IPF idiopathic pulmonary fibrosis, IQR Interquartile range, UIP usual interstitial pneumonia
  3. aComputed tomography (CT) scan pattern according to the diagnostic criteria set by the International Consensus Statement of the American Thoracic Society and European Respiratory Society in 2011[14]